2'-F MODIFIED RNA INTERFERENCE AGENTS
First Claim
Patent Images
1. A method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein said iRNA comprises at least one 2′
- -deoxy-2′
-fluoro (2′
-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand, wherein said modified nucleotide is selected from the group consisting of 2′
-deoxy-2′
-fluoro, 2′
-O-methyl (2′
-OMe), 2′
-methoxyethyl (2′
-MOE), and 2′
-O,4′
-C-methylene (LNA).
1 Assignment
0 Petitions
Accused Products
Abstract
This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein the iRNA comprises at least one 2′-deoxy-2′-fluoro (2′-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand. The invention also relates to compositions comprising a single-stranded oligonucleotide that contains at least one 2′-deoxy-2′-fluoro (2′-F) nucleotide. siRNA molecule containing these oligonucleotides have decreased immunogenicity.
-
Citations
35 Claims
-
1. A method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein said iRNA comprises at least one 2′
- -deoxy-2′
-fluoro (2′
-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand, wherein said modified nucleotide is selected from the group consisting of 2′
-deoxy-2′
-fluoro, 2′
-O-methyl (2′
-OMe), 2′
-methoxyethyl (2′
-MOE), and 2′
-O,4′
-C-methylene (LNA). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- -deoxy-2′
-
14. A method of decreasing the immunogenicity of an iRNA agent, wherein said iRNA comprises at least one 2′
- -deoxy-2′
-fluoro (2′
-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand, and wherein said modified nucleotide is selected from the group consisting of 2′
-deoxy-2′
-fluoro, 2′
-O-methyl, 2′
-methoxyethyl, and 2′
-O,4′
-C-methylene, wherein the siRNA molecule has a decreased immunogenicity relative to an siRNA molecule having the identical sequence but comprising fewer or no 2′
-F modifications.
- -deoxy-2′
- 15. A composition, comprising a single-stranded oligonucleotide represented by formula I:
Specification